Steve Hahn, CEO of Harbinger Health explains Harbinger’s big leap to identify cancer early through a simple blood test and how the company is focusing on access, performance, and ensuring doctors and patients will have the information they need as Harbinger prepares to advance its pioneering product to market. More from Flagship @ JPM2025 here.
More from:
Human Health
What If We Could See Disease Coming and Stop It?
Amanda Kay on a New Approach to Biopharma Partnerships
Pioneering Partnerships: Advancing a Portfolio of Novel Medicines and Vaccines with GSK
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
